Current pharmacological treatments for SARS-COV-2: A narrative review.
Adenosine Monophosphate
/ analogs & derivatives
Adjuvants, Immunologic
/ pharmacology
Alanine
/ analogs & derivatives
Antiviral Agents
/ pharmacology
Betacoronavirus
/ drug effects
COVID-19
Clinical Trials as Topic
Coronavirus Infections
/ drug therapy
Glucocorticoids
/ pharmacology
Heparin, Low-Molecular-Weight
/ pharmacology
Humans
Hydroxychloroquine
/ pharmacology
Immunity, Innate
/ drug effects
Inflammation Mediators
/ pharmacology
Oseltamivir
/ pharmacology
Pandemics
Pneumonia, Viral
/ drug therapy
SARS-CoV-2
Treatment Outcome
COVID-19 Drug Treatment
COVID-19
Clinical trials
Coronavirus
Pharmacological treatments
SARS-CoV-2
Therapies
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
05 Sep 2020
05 Sep 2020
Historique:
received:
13
05
2020
revised:
26
06
2020
accepted:
26
06
2020
pubmed:
1
7
2020
medline:
8
8
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
The novel coronavirus, later identified as SARS-CoV-2, originating from Wuhan in China in November 2019, quickly spread around the world becoming a pandemic. Despite the knowledge of previous coronaviruses, such as those responsible for the SARS and MERS-CoV epidemic, there is no drug or prophylaxis treatment to this day. The rapid succession of scientific findings on SARS-CoV-2 provides a significant number of potential drug targets. Nevertheless, at the same time, the high quantity of clinical data, generated by a large number of rapidly infected people, require accurate tests regarding effective medical treatments. Several in vitro and in vivo studies were rapidly initiated after the outbreak of the pandemic COVID-19. Initial clinical studies revealed the promising potential of remdesivir that demonstrated a powerful and specific in vitro antiviral activity for COVID-19. Promising effects appear to be attributable to hydroxychloroquine. Remdesivir and hydroxychloroquine are being tested in ongoing randomized trials. In contrast, oseltamivir was not effective and corticosteroids are not currently recommended. However, few data from ongoing clinical trials are identifying low molecular weight heparins, innate immune system stimulating agents, and inflammatory modulating agents as potential effective agents. The authors assume that the current pandemic will determine the need for a systematic approach based on big data analysis for identifying effective drugs to defeat SARS-Cov-2. This work is aimed to be a general reference point and to provide an overview as comprehensive as possible regarding the main clinical trials in progress at the moment.
Identifiants
pubmed: 32603692
pii: S0014-2999(20)30420-9
doi: 10.1016/j.ejphar.2020.173328
pmc: PMC7320862
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antiviral Agents
0
Glucocorticoids
0
Heparin, Low-Molecular-Weight
0
Inflammation Mediators
0
Oseltamivir
20O93L6F9H
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Hydroxychloroquine
4QWG6N8QKH
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
173328Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670
pubmed: 32196083
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
Eur J Epidemiol. 1994 Aug;10(4):503-5
pubmed: 7843368
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034
pubmed: 29283993
Hong Kong Med J. 2003 Dec;9(6):399-406
pubmed: 14660806
Antiviral Res. 2018 May;153:85-94
pubmed: 29524445
J Pharm Sci. 1971 Sep;60(9):1281-302
pubmed: 4935981
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Front Immunol. 2019 Jan 24;10:22
pubmed: 30733717
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Birth Defects Res C Embryo Today. 2015 Jun;105(2):140-56
pubmed: 26043938
J Travel Med. 2020 May 18;27(3):
pubmed: 32307545
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219
pubmed: 32391667
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
J Infect Dis. 2015 Dec 15;212(12):1904-13
pubmed: 26198719
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
JMIR Public Health Surveill. 2020 May 5;6(2):e19374
pubmed: 32338613
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Med Virol. 2005 Oct;77(2):147-50
pubmed: 16121363
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Mayo Clin Proc. 2007 May;82(5):638
pubmed: 17493431
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Front Pharmacol. 2021 Sep 02;12:683296
pubmed: 34539392
Lancet. 2003 Jul 26;362(9380):293-4
pubmed: 12892961
Eur J Emerg Med. 2020 Oct;27(5):327-328
pubmed: 32332201
Drugs. 2010 Oct 1;70(14):1885-915
pubmed: 20836579
J Med Chem. 2017 Mar 9;60(5):1648-1661
pubmed: 28124907
Crit Care. 2017 Sep 7;21(1):234
pubmed: 28877748
Biochem J. 2012 May 1;443(3):851-6
pubmed: 22417684
Hum Vaccin Immunother. 2017 Sep 2;13(9):1972-1988
pubmed: 28841363
Inflammation. 2014 Dec;37(6):2091-8
pubmed: 24912813
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
Lancet. 1963 Mar 9;1(7280):552
pubmed: 14014741
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Crit Care. 2019 Mar 27;23(1):99
pubmed: 30917856
Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75
pubmed: 19188392
Antiviral Res. 2013 Nov;100(2):446-54
pubmed: 24084488
J Med Virol. 2020 Jun;92(6):556-563
pubmed: 32104907
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
Lancet. 2020 May 22;:
pubmed: 32450107
PLoS Med. 2016 Mar 01;13(3):e1001967
pubmed: 26930627
Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):206-214
pubmed: 28003465
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Antiviral Res. 2012 Sep;95(3):202-6
pubmed: 22750233
J Med Virol. 2020 Oct;92(10):1890-1901
pubmed: 32293713
Chem Pharm Bull (Tokyo). 1997 Oct;45(10):1688-93
pubmed: 9353898
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Int J Antimicrob Agents. 2020 Apr;55(4):105932
pubmed: 32145363
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
pubmed: 24841269
Infect Genet Evol. 2020 Apr;79:104212
pubmed: 32004758
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463
pubmed: 28769016
J Virol. 2010 Feb;84(3):1289-301
pubmed: 19906920
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
J Antibiot (Tokyo). 2017 May;70(5):495-505
pubmed: 28196978
Antimicrob Agents Chemother. 2002 Apr;46(4):977-81
pubmed: 11897578
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603
J Med Virol. 2020 Oct;92(10):2249
pubmed: 32881013
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
J Pharm Pharmacol. 1979 Nov;31(11):726-9
pubmed: 41900
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
J Med Virol. 2020 May;92(5):479-490
pubmed: 32052466
JAMA. 2020 Apr 21;323(15):1502-1503
pubmed: 32105304
Int J Clin Pharmacol Ther. 2015 Oct;53(10):866-74
pubmed: 26308176
Pharmacotherapy. 2006 Jul;26(7):1018-22
pubmed: 16803426
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Antiviral Res. 2020 May;177:104760
pubmed: 32135219